Avance Clinical Recognized by Frost & Sullivan for Excellence in Biotech CRO Services

• Avance Clinical receives the 2024 Global Customer Value Leadership Award from Frost & Sullivan for its exceptional biotech CRO services.

• The award recognizes Avance Clinical’s ability to deliver high-quality, globally recognized clinical trials and its strong customer-focused approach.

Avance Clinical, a contract research organization (CRO) specializing in biotech, has been awarded the 2024 Global Customer Value Leadership Award by Frost & Sullivan. This recognition underscores the company’s commitment to delivering high-quality clinical trials and its strong focus on customer value.

The award follows Frost & Sullivan’s assessment of the biotech CRO industry, where Avance Clinical was noted for its tailored approach to supporting biotech firms worldwide. The company’s exclusive focus on the biotech sector and over 30 years of clinical research experience across more than 250 therapeutic areas were highlighted as key strengths. With a team of over 330 clinical and regulatory specialists, Avance Clinical operates across Australia, New Zealand, Asia, Europe, and North America, providing comprehensive services from preclinical stages to Phase II/III studies.

As a midsized CRO, Avance Clinical integrates closely with its clients, offering a streamlined approach that optimizes clinical study efficiencies and accelerates timelines. This approach is bolstered by the company’s in-house regulatory team, which helps minimize delays and errors, ensuring that biotech products can swiftly progress through the clinical development process.

“Avance Clinical’s agility and responsiveness make it the ideal partner for small to mid-sized biotech companies,” said Unmesh Lal, Global Research Director at Frost & Sullivan. “Its customer-first approach and deep involvement in client operations position it uniquely in the fast-paced biotech sector.”

The award also recognizes Avance Clinical’s extensive network of over 2,000 clinical trial sites, enabling geographic diversity and rapid patient recruitment. This capacity, coupled with accelerated study start-up durations, ensures faster and more effective clinical trials for biotech clients.